340B drug discounts are drifting from patients to profit, and reform is now on the table
medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…
AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.
CMS to require states to audit Medicaid providers
Kristin Kuchno / beckershospitalreview - CMS Administrator Mehmet Oz, MD, said his administration will require all states to audit healthcare providers to address alleged Medicaid fraud, Politico reported April 21. Dr. Oz unveiled the plan at Politico’s Health Care Summit. Beginning this week, C…
AI Summary: CMS is requiring states to audit Medicaid providers as part of a new oversight initiative aimed at tightening program integrity and provider revalidation. The policy has sparked high‑level calls for nationwide reviews and a proposed 50‑state audit effort, signaling heightened federal scrutiny and potential changes to enrollment, billing and provider eligibility processes.
UnitedHealth Group boosts 2026 outlook as it posts Q1 earnings, revenue beat
fiercehealthcare - UnitedHealth Group is boosting its 2026 outlook after seeing some payoff to its efforts to control medical costs.
AI Summary: UnitedHealth reported stronger‑than‑expected first‑quarter results and upgraded its 2026 profit outlook, citing operational momentum and pricing moves that buoyed investor confidence. Coverage also captures contrasting takes on quarterly performance and the insurer’s ongoing strategy to reclaim margin, signaling a company shifting from defense to offense in a softening healthcare market.
- Earnings beat: UnitedHealth posts Q1 strength, raises 2026 outlook (3)
- Margin playbook: member cuts, buybacks, and broker pressures (3)
- Optum tech and exec pay: AI bets and compensation scrutiny (4)
- All Other Stories
Earnings beat: UnitedHealth posts Q1 strength, raises 2026 outlook
Margin playbook: member cuts, buybacks, and broker pressures
Optum tech and exec pay: AI bets and compensation scrutiny
All Other Stories
RFK Jr. says China is 'eating our lunch' in biotech advances
Zachary Brennan / endpoints - China is "eating our lunch" on new drug approvals and clinical trial starts, HHS Secretary Robert F. Kennedy Jr. told Congress Tuesday, while praising the FDA's actions so far. "We are losing scientists, we're losing ...
AI Summary: Robert F. Kennedy Jr. publicly criticized U.S. biotech competitiveness—singling out China as gaining ground—and declined to fully endorse the new CDC vaccine director, blending industry critique with public‑health ambivalence. His comments underscore tensions between political positioning and health policy messaging while rattling stakeholders who prefer facts over theatrical proclamations.
- Kennedy defensive in hearings, balancing White House and base (4)
- Kennedy hesitates on CDC director, vaccine reports spark debate (5)
- On Pharma frontlines: Kennedy warns China is eating our lunch (3)
- All Other Stories